Ignite Creation Date:
2024-05-06 @ 3:03 PM
Last Modification Date:
2024-10-26 @ 1:41 PM
Study NCT ID:
NCT04502394
Status:
UNKNOWN
Last Update Posted:
2022-08-04
First Post:
2020-07-27
Brief Title:
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With RR DLBCL or RR CLL
Sponsor:
Kartos Therapeutics Inc
Organization:
Kartos Therapeutics Inc
Study Overview
Official Title:
An Open-Label Multicenter Phase 1b2 Study of the Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With RelapsedRefractory Diffuse Large B-cell Lymphoma or RelapsedRefractory Chronic Lymphocytic Leukemia
Status:
UNKNOWN
Status Verified Date:
2022-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluates KRT-232 a novel oral small molecule inhibitor of MDM2 combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia Participants must be relapsedrefractory having failed prior therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None